Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) – Drugs in Development, 2021

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Histone Deacetylase 4 – Drugs in Development, 2021, outlays comprehensive information on the Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) – Histone deacetylase 4 (HDAC4) is a protein encoded by the HDAC4 gene. It is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. It acts via the formation of large multiprotein complexes. The molecules developed by companies in Phase II and Preclinical stages are 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Report covers products from therapy areas Oncology and Cardiovascular which include indications Congestive Heart Failure (Heart Failure), Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Essential Thrombocythemia, Follicular Lymphoma, Gallbladder Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Multiple Myeloma (Kahler Disease), Mycosis Fungoides, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Pancreatic Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Pulmonary Arterial Hypertension, Rhabdomyosarcoma and Sezary Syndrome.

Furthermore, this report also reviews key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)

– The report reviews Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

– The report assesses Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

4SC AG

KYAN Therapeutics Inc

MEI Pharma Inc

Mirati Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) - Overview

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) - Companies Involved in Therapeutics Development

4SC AG

KYAN Therapeutics Inc

MEI Pharma Inc

Mirati Therapeutics Inc

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) - Drug Profiles

Gene Therapy to Activate HDAC4 for Heart Failure - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KYAN-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MC-1568 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mocetinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pracinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resminostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) - Dormant Products

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) - Discontinued Products

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) - Product Development Milestones

Featured News & Press Releases

Jul 03, 2020: Helsinn and MEI stop Phase III trial of pracinostat in AML

May 13, 2020: Helsinn and MEI Pharma announce updated clinical data from the phase 2 study evaluating pracinostat in combination with azacitidine in patients with high/very-high risk myelodysplastic syndromes

Feb 14, 2019: Helsinn and MEI Pharma announce publication of phase II data for Pracinostat in combination with Azacitidine in the frontline treatment of older AML patients unfit for intensive chemotherapy, in Blood Advance

Jan 28, 2019: 4SC’s pivotal RESMAIN study of resminostat in CTCL receives second positive safety review

Dec 03, 2018: Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting

Nov 20, 2018: 4SC reaches significant milestone with enrollment of 100 patients in pivotal RESMAIN study of resminostat as CTCL maintenance therapy

Nov 09, 2018: Mirati presents data from ongoing phase 2 clinical trial of Mocetinostat in combination with Durvalumab at the SITC 33rd Annual Meeting

Nov 05, 2018: Mirati to present new data from ongoing phase 2 clinical trial on mocetinostat and durvalumab at the SITC 33rd Annual Meeting

Nov 01, 2018: MEI Pharma to present data from Phase 2 trial of Pracinostat at ASH 2018

Jun 28, 2018: New data supports resminostat’s mechanism of action in CTCL maintenance therapy

May 31, 2018: MEI Pharma and Helsinn Group Announce Successful Interim Analysis of Pracinostat/Azacitidine Phase 2 Combination Study in Higher Risk Myelodysplastic Syndrome (MDS) Patients

May 30, 2018: Helsinn Group and MEI Pharma Announce Upcoming Presentation at ASCO 2018 on the design of the Phase III PRIMULA study of Pracinostat in combination with azacitidine for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit f

Apr 19, 2018: Phase II study of 4SC’s resminostat in biliary tract cancer in Japan is initiated

Apr 11, 2018: Yakult Honsha recruits first Japanese patient in 4SC’s pivotal RESMAIN study of resminostat in CTCL

Mar 27, 2018: Yakult Honsha joins 4SC’s pivotal RESMAIN study of resminostat in CTCL - 4SC receives milestone payment

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by 4SC AG, 2021

Pipeline by KYAN Therapeutics Inc, 2021

Pipeline by MEI Pharma Inc, 2021

Pipeline by Mirati Therapeutics Inc, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports